$IDYA
IDEAYA Biosciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017204 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $29.70M $5.851M $11.36M
YoY Change 230.87% -33.18% 56.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.667M $5.554M $5.923M
YoY Change 28.56% 15.04% 22.88%
% of Gross Profit
Research & Development $22.37M $22.80M $19.66M
YoY Change 44.31% 52.19% 69.95%
% of Gross Profit
Depreciation & Amortization $569.0K $510.0K $464.0K
YoY Change 26.16% 14.35% 21.47%
% of Gross Profit
Operating Expenses $29.04M $28.35M $25.58M
YoY Change 40.36% 43.13% 56.14%
Operating Profit $660.0K -$22.50M -$14.22M
YoY Change -105.63% 103.59% 55.67%
Interest Expense $955.0K $443.0K $207.0K
YoY Change 629.01% 325.96% 88.18%
% of Operating Profit 144.7%
Other Income/Expense, Net $955.0K $443.0K $207.0K
YoY Change 629.01% 325.96% 81.58%
Pretax Income $1.615M -$22.06M -$14.01M
YoY Change -113.94% 101.48% 55.35%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $1.615M -$22.06M -$14.01M
YoY Change -113.94% 101.48% 55.34%
Net Earnings / Revenue 5.44% -376.96% -123.36%
Basic Earnings Per Share $0.04 -$0.57 -$0.36
Diluted Earnings Per Share $0.04 -$0.57 -$363.1K
COMMON SHARES
Basic Shares Outstanding 39.31M 38.66M 38.63M
Diluted Shares Outstanding 41.11M 38.66M 38.59M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $386.2M $268.6M $252.6M
YoY Change 46.0% -2.03% -16.44%
Cash & Equivalents $102.0M $49.11M $55.29M
Short-Term Investments $284.3M $219.5M $197.3M
Other Short-Term Assets $3.744M $3.281M $2.753M
YoY Change 10.31% -23.48% -5.07%
Inventory
Prepaid Expenses
Receivables $3.449M $288.0K $697.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $393.4M $272.2M $256.0M
YoY Change 46.28% -2.72% -16.92%
LONG-TERM ASSETS
Property, Plant & Equipment $6.679M $7.163M $5.274M
YoY Change 41.9% 46.24% -45.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $7.691M $55.17M $93.63M
YoY Change -93.66% 44.22% 1055.9%
Other Assets $146.0K $174.0K $256.0K
YoY Change -32.72% -80.6% 28.0%
Total Long-Term Assets $17.47M $65.82M $102.8M
YoY Change -86.61% 35.39% 474.4%
TOTAL ASSETS
Total Short-Term Assets $393.4M $272.2M $256.0M
Total Long-Term Assets $17.47M $65.82M $102.8M
Total Assets $410.9M $338.0M $358.9M
YoY Change 2.87% 2.93% 10.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.645M $4.227M $3.364M
YoY Change 69.38% 100.52% 158.77%
Accrued Expenses $16.99M $16.23M $12.63M
YoY Change 42.85% 63.77% 35.78%
Deferred Revenue $10.27M $35.85M $39.22M
YoY Change -55.23%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.73M $58.09M $56.96M
YoY Change -15.3% 62.39% 57.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.411M $10.60M $13.24M
YoY Change 156750.0% -79.77% -76.68%
Total Long-Term Liabilities $9.411M $10.60M $13.24M
YoY Change 156750.0% -79.77% -76.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.73M $58.09M $56.96M
Total Long-Term Liabilities $9.411M $10.60M $13.24M
Total Liabilities $42.14M $68.69M $70.20M
YoY Change -48.5% -22.07% -24.52%
SHAREHOLDERS EQUITY
Retained Earnings -$211.2M -$212.8M -$190.8M
YoY Change 33.25% 44.76%
Common Stock $584.0M $485.8M $482.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $368.8M $269.3M $288.7M
YoY Change
Total Liabilities & Shareholders Equity $410.9M $338.0M $358.9M
YoY Change 2.87% 2.93% 10.05%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $1.615M -$22.06M -$14.01M
YoY Change -113.94% 101.48% 55.34%
Depreciation, Depletion And Amortization $569.0K $510.0K $464.0K
YoY Change 26.16% 14.35% 21.47%
Cash From Operating Activities -$24.17M -$19.99M -$19.65M
YoY Change 93.82% 54.57% 43.16%
INVESTING ACTIVITIES
Capital Expenditures -$1.101M -$1.941M $401.0K
YoY Change 140.39% 234.08% -60.02%
Acquisitions
YoY Change
Other Investing Activities -$17.58M $15.26M -$17.36M
YoY Change -68.52% -131.26% -146.37%
Cash From Investing Activities -$18.68M $13.32M -$17.76M
YoY Change -66.82% -126.96% -148.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 95.70M 491.0K 653.0K
YoY Change 10.28% -96.93% -98.45%
NET CHANGE
Cash From Operating Activities -24.17M -19.99M -19.65M
Cash From Investing Activities -18.68M 13.32M -17.76M
Cash From Financing Activities 95.70M 491.0K 653.0K
Net Change In Cash 52.85M -6.185M -36.76M
YoY Change 193.58% -86.65% -156.8%
FREE CASH FLOW
Cash From Operating Activities -$24.17M -$19.99M -$19.65M
Capital Expenditures -$1.101M -$1.941M $401.0K
Free Cash Flow -$23.06M -$18.05M -$20.05M
YoY Change 92.05% 46.13% 36.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
218000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
784000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
435000
us-gaap Share Based Compensation
ShareBasedCompensation
5649000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001676725
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38915
dei Entity Registrant Name
EntityRegistrantName
IDEAYA Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4268251
dei Entity Address Address Line1
EntityAddressAddressLine1
7000 Shoreline Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 350
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
443-6209
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
IDYA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39305802
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49106000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92046000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
219514000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
154724000
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
288000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1103000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3281000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3123000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
272189000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
250996000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
106000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
106000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
55171000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
121293000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7163000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4763000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3204000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3898000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
174000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
291000
CY2022Q2 us-gaap Assets
Assets
338007000
CY2021Q4 us-gaap Assets
Assets
381347000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4227000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2100000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16230000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12320000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
35849000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
29040000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1783000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1699000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
58089000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45159000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8025000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31192000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2572000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3482000
CY2022Q2 us-gaap Liabilities
Liabilities
68686000
CY2021Q4 us-gaap Liabilities
Liabilities
79833000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38704010
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38704010
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38533045
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38533045
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
485763000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
478970000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3629000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-712000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212817000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176748000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
269321000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301514000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
338007000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
381347000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5851000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8756000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17210000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16003000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5851000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8756000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17210000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16003000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22796000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14979000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42451000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26546000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5554000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4828000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11478000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9643000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
28350000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
19807000
us-gaap Operating Expenses
OperatingExpenses
53929000
us-gaap Operating Expenses
OperatingExpenses
36189000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22499000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11051000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36719000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20186000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
443000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
650000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22056000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10947000
us-gaap Net Income Loss
NetIncomeLoss
-36069000
us-gaap Net Income Loss
NetIncomeLoss
-19968000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-825000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2917000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22881000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10950000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38986000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19979000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38660971
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38660971
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32854926
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32854926
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38626659
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38626659
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32321481
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32321481
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
288667000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-66000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
122000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
435000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3044000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-825000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22056000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
269321000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
233125000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15454000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
243000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
327000
CY2021Q2 idya Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2058000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10947000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
240260000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301514000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-75000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5649000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2917000
us-gaap Net Income Loss
NetIncomeLoss
-36069000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
269321000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
198274000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57286000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
355000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
327000
idya Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares
21000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3976000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000
us-gaap Net Income Loss
NetIncomeLoss
-19968000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
240260000
us-gaap Profit Loss
ProfitLoss
-36069000
us-gaap Profit Loss
ProfitLoss
-19968000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
974000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
826000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-518000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-899000
us-gaap Share Based Compensation
ShareBasedCompensation
3976000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
694000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
642000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-815000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-552000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
51000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1719000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1916000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
796000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3099000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1724000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-16358000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13633000
idya Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-826000
idya Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-749000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39639000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26654000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2342000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1581000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
102222000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
133046000
idya Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
100119000
idya Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
117663000
idya Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
idya Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
4018000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4445000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12946000
idya Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts
-75000
idya Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts
57308000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
784000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
327000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
435000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
355000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1144000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57990000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42940000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18390000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92152000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72143000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49212000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90533000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49106000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90427000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
106000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
106000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49212000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90533000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
us-gaap Interest Paid Net
InterestPaidNet
32000
us-gaap Interest Paid Net
InterestPaidNet
37000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1021000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
378000
idya Unpaid Offering Costs
UnpaidOfferingCosts
0
idya Unpaid Offering Costs
UnpaidOfferingCosts
171000
idya Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
0
idya Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
21000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212800000
CY2022Q2 idya Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
323800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Substantially all the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable represents amounts due from GlaxoSmithKline. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection.</span></p>
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
278313000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3629000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274684000
CY2022Q2 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
327508000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3629000
CY2022Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
323879000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
276729000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
720000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
276017000
CY2021Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
368554000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
720000
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
367842000
CY2022Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13609000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10360000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6446000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5597000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7163000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4763000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000.0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2022Q2 idya Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11219000
CY2021Q4 idya Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7864000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3475000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3971000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
726000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
485000
CY2022Q2 idya Accrued Fixed Assets Current
AccruedFixedAssetsCurrent
810000
CY2021Q4 idya Accrued Fixed Assets Current
AccruedFixedAssetsCurrent
0
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16230000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12320000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.875
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.878
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.960
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.875
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2022Q2 idya Number Of Common Stock Voting Rights Held Per Share
NumberOfCommonStockVotingRightsHeldPerShare
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6904287
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5146427
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.899
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.960
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.036
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3044000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2058000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5649000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3976000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
30100000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
22200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M25D
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M9D
CY2022Q2 idya Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
38660971
CY2021Q2 idya Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
32864249
idya Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
38626659
idya Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
32334859
CY2021Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
9323
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.027
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.030
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.030
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
13378
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38660971
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38660971
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32854926
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32854926
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38626659
CY2022Q2 idya Collaboration Revenue
CollaborationRevenue
5851000
CY2021Q2 idya Collaboration Revenue
CollaborationRevenue
8756000
idya Collaboration Revenue
CollaborationRevenue
17210000
idya Collaboration Revenue
CollaborationRevenue
16003000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
60232000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
17210000
idya Cash Received For Cost Reimbursements
CashReceivedForCostReimbursements
564000
idya Gross Increase In Accounts Receivable During Period
GrossIncreaseInAccountsReceivableDuringPeriod
288000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
43874000
idya Reimbursement Period Of Costs Incurred
ReimbursementPeriodOfCostsIncurred
P75D
idya Number Of Additional Customer Options Under The Mat2 A Program
NumberOfAdditionalCustomerOptionsUnderTheMat2AProgram
2
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
45623000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22056000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10947000
us-gaap Net Income Loss
NetIncomeLoss
-36069000
us-gaap Net Income Loss
NetIncomeLoss
-19968000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38626659
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32321481
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32321481
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4922224
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3654150

Files In Submission

Name View Source Status
0000950170-22-017204-index-headers.html Edgar Link pending
0000950170-22-017204-index.html Edgar Link pending
0000950170-22-017204.txt Edgar Link pending
0000950170-22-017204-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
idya-20220630.htm Edgar Link pending
idya-20220630.xsd Edgar Link pending
idya-ex31_1.htm Edgar Link pending
idya-ex31_2.htm Edgar Link pending
idya-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
idya-20220630_lab.xml Edgar Link unprocessable
idya-20220630_def.xml Edgar Link unprocessable
idya-20220630_cal.xml Edgar Link unprocessable
idya-20220630_htm.xml Edgar Link completed
idya-20220630_pre.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending